🇺🇸 FDA
Patent

US 11932852

Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

granted A61PA61P21/00A61P27/02

Quick answer

US patent 11932852 (Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof) held by Benitec IP Holdings Inc. expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Benitec IP Holdings Inc.
Grant date
Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P21/00, A61P27/02